USIDNET- LeBien Visiting Professor
The LeBien Visiting Professor Program promotes improved knowledge about the diagnosis and treatment of primary immunodeficiency diseases. Teaching hospitals throughout the United States may submit a request for a leading clinical immunologist to lead Grand Rounds or present at other educational activities, such as bedside rounds or house staff and/or medical residents conferences.
If you are interested in participating in this exciting program, please send a brief (one page) letter to the Immune Deficiency Foundation, Attn: IDF & USIDNet LeBien Visiting Professor Program, 40 West Chesapeake Ave., Suite 308, Towson, MD 21204 by November 30, 2009, stating your desire toparticipate in the program. The lettershould include a tentative list ofteaching and clinical activities for theVisiting Professor and information on how your training program would benefit from a Visiting Professorship.
The benefits of the USIDNET/IDF's (IDF & USIDNET’s) LeBien Visiting Professor Program include:
* Increases knowledge of the diagnosis and treatment of primary immunodeficiency diseases
* Professional medical educational materials to accompany the program
|
Date of Visit
|
Medical Institution
|
Selected VP
|
|
1/14-1/15
|
Tulane University
|
Dr. William Shearer
|
|
3/10-3/11
|
Hershey Medical Center
|
Dr. Troy Torgerson
|
|
3/17-3/19
|
Morehouse School of Medicine
|
Dr. Rebecca Buckley
|
|
4/2-4/3
|
University of North Carolina-Chapel Hill
|
Dr. Steven Holland
|
|
4/23-4/24
|
University of Iowa Children's Hospital
|
Dr. Hans Ochs
|
|
5/14-5/15
|
Medical College of Wisconsin
|
Dr. Jordan Orange
|
|
5/18-5/20
|
University of Tennessee College of Medicine
|
Dr. Rebecca Buckley
|
|
10/5-10/6
|
St. Johns Hospital and Medical Center
|
Dr. Cunningham-Rundles
|
|
11/3
|
University of Texas Medical School-Houston
|
Dr. Steven Holland
|
For more information, contact Diana Gill at 443-632-2545 or email dgill@primaryimmune.org.
The LeBien Visiting Professor Program is funded in part by the IDF Core Service Sponsors: Baxter Healthcare Corporation, CSL Behring, Grifols, IgG America / ASD Healthcare, Octapharma and Talecris Biotherapeutics, as well as the United States Immunodeficiency Network (USIDNET).